Dr Giulia Segafredo (Medicines Patent Pool, Geneva, Switzerland) and Dr Dario Trapani (European Institute of Oncology, Milan, Italy) talk to ecancer about research they presented at ASCO 2025.

Lung cancer, especially advanced non-small cell lung cancer, poses a significant health challenge. Immunotherapy, particularly PD-1 and PD-L1 inhibitors, shows promise but is often unaffordable. Research aims to set fair pricing in lower middle-income countries like India and South Africa, assessing cost-effectiveness of treatments compared to chemotherapy.

Strategies for price reduction, including dose optimisation and biosimilars, are explored to enhance accessibility.